Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GNPXthis companyGenprex, Inc.	$2.09	-0.1×	0.21×	0×	0.4×	7438.7%	0.0%	0.0%	0.0%	-203.8%	-194.3%	-938.0%	0×	0.51×	-20.97×	3.84×	0.0%	2	-16.5	2	B-
BIVIBioVie Inc.	$1.31	-0.64×	0×	0×	397,772.85×	87659892.5%	0.0%	0.0%	0.0%	-0.0%	-0.0%	-135339.5%	0.03×	397,773.5×	-1,265.39×	3.59×	0.0%	2	-39.28	3	B
CNSPCNS Pharmaceuticals, Inc.	$4.16	-0.15×	0.51×	0×	0.29×	75.0%	0.0%	0.0%	0.0%	-350.5%	-329.5%	-594.1%	0.07×	0.43×	-1,049.68×	1.98×	0.0%	1	-7.36	2	C+
GRIGRI Bio, Inc.	$1.86	-0.06×	0.11×	0×	0.62×	4375.4%	0.0%	0.0%	0.0%	-199.0%	-197.0%	-1502.1%	0.01×	0.68×	0×	3.25×	0.0%	1	-6.79	3	B
JAGXJaguar Health, Inc.	$0.42	-0.04×	-0.13×	0.19×	-0.87×	-26951593.0%	67.2%	-391.9%	-464.2%	309.1%	-178.3%	265.8%	-2.52×	-0.82×	673.25×	0.5×	0.0%	3	-20.02	2	C
LIMNLiminatus Pharma, Inc. Class A Common Stock	$2.65	-1.42×	-1.48×	0×	-1.56×	-235.7%	0.0%	0.0%	0.0%	104.0%	35.6%	-68.9%	-0.15×	-0.11×	-13.75×	0.05×	0.0%	2	-28.31	1	D+
Peer median	—	-0.15×	0×	0×	0.29×	75.0%	0.0%	0.0%	0.0%	-0.0%	-178.3%	-594.1%	0.01×	0.43×	-13.75×	1.98×	0.0%	2	-20.02	2	—